

Acta Scientifica Naturalis

Former Annual of Konstantin Preslavsky University – Chemistry, Physics, Biology, Geography

Journal homepage: http://www.shu.bg

Received: 30.10.2016 Accepted: 11.01.2017

Synthesis and properties of N-alkyl(phenyl)amido-O-methyl-1,2-alkadienephosphonates Dobromir D. Enchev

Department of Organic Chemistry, Faculty of Natural Sciences, "K. Preslavsky" University, 115 Universitetska Str., 9712 Shumen, Bulgaria e-mail: <u>enchev@shu.bg</u>

Abstract: The synthesis of the titled compounds has been described. Their reactivity towards electrophilic and nucleophilic reagents has been investigated.

Keywords: 1,2-alkadienephosphonates, 2,5-dihydro-1,2-oxaphospholes, -ketophosphonates


Introduction

It is well known that 1,2-alkadienephosphonates react with different kinds of reagents due to their unique structure which allowed activation of different reaction centers in their molecules, i.e. 1,2- and 2,3-duble bonds or phosphoryl group, via variation of kind and number of the substituents at P, C1 and C3 atoms of the 1,2- alkadienephosphonate system of double bonds[1].

Continuing our investigations in the area of the chemistry of N-containing-1,2-alkadiene-phosphonates[2-8], we would like to report our results on the synthesis and chemical behavior of the titled compounds.

Results and Discussion


The methyl-N-alkyl(phenyl)-(3-methylalka-1,2-dienyl)phosphonamidates **2a-f** were synthesized via procedure described[2-8], i.e. via nucleophilic displacement of the two chlorine atoms at phosphorus in the 1,2-alkadienephosphonic dichlorides **1a,b** with metoxy- and alkyl(phenyl)amino groups(Scheme 1):



Scheme1. Synthesis of methyl-N-alkyl(phenyl)-(3-methylalka-1,2-dienyl)phosphonamidates 2a-f

The obtained methyl-N-alkyl(phenyl)-(3-methylalka-1,2-dienyl)phosphonamidates **2a-f** were investigated in the reactions with sulfenyl- and selenenylbromides. In all cases regardless of the kind of the electrophile 2,5-dihydro-1,2-oxaphosphole-2-oxide derivatives **3a-l** were obtained(Scheme 2.):


ASN, Vol 4, No 1, Pages 6-12, 2017



Scheme 2. Synthesis of 2,5-dihydro-1,2-oxaphosphole-2-oxide derivatives 3a-l

All spectral data confirm the obtaining of the products **3a-l**. Thus the characteristic band for allenic system in the IR spectra of **2a-f** at 1980-1990cm⁻¹, disappears in the IR spectra of the **3a-l** and new characteristic band for endocyclic carbon-carbon double bond appears at 1590-1580cm⁻¹. The signal for metoxy-group in the ¹H NMR spectra of **2a-f** disappears in the ¹H NMR spectra of **3a-l**. The multiplet signal for olephinic proton in the ¹H NMR spectra of **2a-f** disappears in the ¹H NMR spectra of **3a-l** while two doublets for the proton at position 3 of the oxaphosphole ring appear. The signal for ³¹P in the ³¹P NMR spectra of **2a-f** is at 16.8-17.3ppm while the signal for ³¹P for compounds **3a-l** is at 27.9-32.0ppm. The obtaining of 3a-l was also confirmed by the elemental analysis data.

The interaction of the titled compounds with diethylamine leads to obtaining of β -ketophosphonates **4a-f** (Scheme 3):



Scheme 3. Synthesis of methyl-P-(3-methyl-2-oxoalkyl)-N-alkylphosphoamidates 4a-f

The obtaining of the products **4a-f** was confirmed by their spectral data. Thus the characteristic band for allenic system in the IR spectra of **2a-f** at 1980-1990cm⁻¹, disappears in the IR spectra of the **4a-f** and new characteristic band for carbonyl group appear at 1690-1700cm⁻¹. The signal for metoxy-group in the ¹H NMR spectra of **2a-f** present also in the spectra of **4a-f**. The multiplet signal for olephinic proton in the ¹H NMR spectra of **2a-f** disappears in the ¹H NMR spectra of **3a-l** while two doublets for the proton at position 3 of the oxaphosphole ring appear. The signal for ³¹P in the ³¹P NMR spectra of **2a-f** is at 16.8-17.3ppm while the signal for ³¹P for compounds **4a-f** is at 27.9-32.0ppm. The obtaining of **4a-f** was also confirmed by the elemental analysis data.

Experimental

Analytical Methods

The ¹H NMR spectra were measured at normal probe temperature on a spectrometer Bruker Avance DRX 250MHz using TMS as internal reference in CDCl₃ solution. Chemical shifts are given in *ppm* and are positively

7

Corresponding author: enchev@shu.bg DOI: 10.1515/asn-2017-0002



ASN, Vol 4, No 1, Pages 6-12, 2017

downfield from the internal standard. The IR spectra were run on a Shimadzu FTR spectrophotometer. Elemental analyses were carried out by the University of Shumen Microanalytical Service Laboratory.

Starting Materials

The dichlorides **1a**,**b** were prepared according to the procedure described[10].

Phenylselenenylbromide is commercially available. Phenylsulfenylbromide was synthesized according to the procedure described [9].

The solvents were purified by standard methods. All reactions were carried out in oven-dried glassware under an argon atmosphere and exclusion of moisture. All compounds were checked for their purity on TLC plates.

Synthesis of the compounds 2a-f

General Procedure:

To a solution of 5mmol of the appropriate dichloride **1a,b** in dry diethyl ether at 0 to -5° C and stirring a solution of 5mmol of methanol and 5mmol of pyridine was added, followed by addition of the mixture of 5mmol from the appropriate amine and 5 mmol of pyridine, dissolved in the same solvent. After one hour of stirring reaction mixture rest for a night, the precipitate was filtered off, the solvent was removed under low pressure and the residue was distilled *in vacuum*.

 $\begin{array}{l} \textit{Methyl-N-propyl-P-(3-methylbuta-1,2-dienyl)phosphonamidate } \textbf{2a}. C_9H_{18}NO_2P; Calcd.: P 15.24, N 6.89 \%; \\ \textit{Found: P 15.19, N 6.82 \%; IR: v(cm^{-1}) 1986 } _{(C=C=C)}, 1256 } _{(P=O)}, 980 } _{(P=O-C)}, {}^{1}H \ \textit{NMR} \ (CDCl_3): \delta/\textit{ppm} 5.05-4.95(m, 1H, (\underline{HC}=)); 3.39(d, {}^{3}J_{HP} 11.25Hz, 3H, (O\underline{Me})); 2.67-2.54(m, 2H, (CH_3CH_2\underline{CH_2}N)); 1.46(s, 3H, =C\underline{CH_3})); 1.51(s, 3H, (=C\underline{CH_3})); 2.00(d, {}^{2}J_{HP} 10.00Hz, 1H, (N\underline{H})); 1.28-1.19(m, 2H, (CH_3\underline{CH_2}CH_2N)); 0.91(t, 3H, (\underline{CH_3}CH_2CH_2N)); {}^{31}P \ \textit{NMR}(CDCl_3) \ \delta/\textit{ppm}: {}^{31}P \ 17.1; yellow-red liquid, b.p.({}^{\circ}C/0.5mmHg) \ uncorrected 136-138; Yield (\%) 85. \\ \end{array}$

 $\begin{array}{l} \textit{Methyl-N-butyl-P-(3-methylbuta-1,2-dienyl)phosphonamidate } \mbox{2b. } C_{10}H_{20}NO_2P; \mbox{Calcd.: P 14.26, N 6.44 \%;} \\ \textit{Found: P 14.21, N 6.40 \%; IR: $v(cm^{-1}) 1988_{(C=C=C)}, 1260_{(P=O)}, 980_{(P-O-C)}, {}^{1}H \mbox{NMR (CDCl}_3): $\delta/ppm 5.04-4.97(m, 1H, (HC=)); 3.38(d, {}^{2}J_{HP} 11.25Hz, 3H, (O\underline{Me})); 2.66-2.53(m, 2H, (CH3CH2CH_2\underline{CH}_2N)); 1.46(s, 3H, =C\underline{CH}_3)); 1.51(s, 3H, (=C\underline{CH}_3)); 2.00(d, {}^{2}J_{HP} 10.00Hz, 1H, (N\underline{H})); 1.27-1.18(m, 2H, (CH_3CH_2\underline{CH}_2CH_2N)); 1.16-0.99(m, 2H, (CH_3\underline{CH}_2CH_2CH_2N)); 0.63(t, 3H, (\underline{CH}_3CH_2CH_2CH_2N)); {}^{31}P \mbox{NMR(CDCl}_3) \mbox{\delta/ppm: } {}^{31}P \ 16.8; \mbox{yellow-red liquid, b.p. (}^{\circ}C/0.5mmHg) \mbox{ uncorrected 138-140; Yield (} 82. \end{array}$

Methyl-P-3-methylbuta-1,2-dienyl-N-phenylphosphonamidate **2c**. $C_{12}H_{16}NO_2P$; Calcd.: P 13.06, N 5.90 %; Found: P 13.00, N 5.88 %; IR: v(cm⁻¹) 1987 (C=C=C), 1264 (P=O), 980 (P-O-C), ¹H NMR (CDCl₃): δ /ppm 7.29-7.17(m, 2H, (Ph)); 7.05(d, ²J_{HH} 7.75Hz, 1H, (Ph)); 6.89(t, ²J_{HH} 7.25Hz, 2H, (Ph)); 5.45-5.35(m, 1H, (<u>H</u>C=)); 4.03(d, ²J_{HP} 11.5Hz, 1H, (N<u>H</u>)); 3.74(d, ³J_{HP} 11.5Hz, 3H, OMe)); 1.46(s, 3H, =C<u>CH</u>₃)); 1.51(s, 3H, (=C<u>CH</u>₃)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 17.0; cryst., m.p. (°C) uncorrected 143-146, Yield (%) 80.

 $\begin{array}{l} \textit{Methyl-N-propyl-P-(3-methylpenta-1,2-dienyl)phosphonamidate} \quad \textbf{2d.} \ C_{10}H_{20}NO_2P; \ Calcd.: P \ 14.26, N \ 6.44 \ \%; \\ Found: P \ 14.21, N \ 6.40 \ \%; \ IR: v \ (cm^{-1}) \ 1990 \ _{(C=C=C)}, \ 1258 \ _{(P=O)}, \ 980 \ _{(P-O-C)}, \ ^1H \ NMR \ (CDCl_3): \ \delta/ppm \ 5.04- \\ 4.97(m, \ 1H, \ (HC=)); \ 3.38(d, \ ^2J_{HP} \ 11.25Hz, \ 3H, \ (OMe)); \ 2.67-2.54(m, \ 2H, \ (CH_3CH_2CH_2N)); \ 1.82-1.68(m, \ 3H, \ (\underline{NH}), \ (CH_3CH_2)); \ 1.49(dd, \ ^3J_{HH} \ 10,00Hz, \ ^4J_{HH} \ 3.53Hz, \ 3H, \ (=C\underline{CH}_3)); \ 1.28-1.19(m, \ 2H, \ (CH_3\underline{CH}_2CH_2N)); \\ 0.77(dt, \ ^2J_{HH} \ 1.25Hz, \ 3H, \ (\underline{CH}_3CH_2)); \ 0.91(t, \ 3H, \ (\underline{CH}_3CH_2CH_2N)); \ ^{31}P \ NMR(CDCl_3) \ \delta/ppm: \ ^{31}P \ 16.8; \ yellow-red \ liquid, \ b.p. \ (^{\circ}C \ /0.5 \ mmHg) \ uncorrected \ 137-139; \ Yield \ (\% \) \ 87. \end{array}$

 $\begin{array}{l} \textit{Methyl-N-butyl-P-(3-methylpenta-1,2-dienyl)phosphonamidate} \ \ \textbf{2e}. \ C_{11}H_{22}NO_2P; \ Calcd.: P \ 13.39, N \ 6.05 \ \%; \\ \hline Found: P \ 13.34, N \ 6.00 \ \%; \ IR: v \ (cm^{-1}) \ 1989 \ _{(C=C=C)}, \ 1260 \ _{(P=O)}, \ 980 \ _{(P-O-C)}, \ ^{1}H \ NMR \ (CDCl_3): \ \delta/ppm \ 5.04-4.97(m, 1H, (HC=)); \ 3.38(d, \ ^{2}J_{HP} \ 11.25Hz, \ 3H, (OMe)); \ 2.66-2.53(m, 2H, (CH_{3}CH_{2}CH_{2}CH_{2}N)); \ 1.82-1.68(m, 3H, (\underline{NH}), (CH_{3}CH_{2})); \ 1.49(dd, \ ^{3}J_{HH} \ 10.00Hz, \ ^{4}J_{HH} \ 3.53Hz, \ 3H, \ (=C\underline{CH}_{3})); \ 1.27-1.18(m, 2H, \ (CH_{3}CH_{2}CH_{2}CH_{2}CH_{2}N)); \ 1.16-0.99(m, 2H, \ (CH_{3}CH_{2}CH_{2}CH_{2}CH_{2}N)); \ 0.77(dt, \ ^{2}J_{HH} \ 1.25Hz, \ 3H, \ (\underline{CH}_{3}CH_{2})); \ 0.63(t, \ 3H, \ (\underline{CH}_{3}CH_{2}CH_{2}CH_{2}CH_{2}N)); \ ^{31}P \ NMR(CDCl_{3}) \ \delta/ppm: \ ^{31}P \ 17.3; \ yellow-red \ liquid, \ b.p. \ (^{\circ}C/0.5mmHg) \ uncorrected \ 142-145; \ Yield \ (\%) \ 81. \end{array}$



Methyl-P-3-methylpenta-1,2-dienyl-N-phenylphosphonamidate **2f**. $C_{13}H_{18}NO_2P$; Calcd.: P 12.33, N 5.57 %; Found: P 12.29, N 5.52 %; IR: v (cm⁻¹) 1992 (C=C=C), 1259 (P=O), 980 (P-O-C), ¹H NMR (CDCl₃): δ /ppm 7.29-7.17(m, 2H, (Ph)); 7.05(d, ²J_{HH} 7.75Hz, 1H, (Ph)); 6.89(t, ²J_{HH} 7.25Hz, 2H, (Ph)); 5.45-5.35(m, 1H, (<u>H</u>C=)); 4.03(d, ²J_{HP} 11.5Hz, 1H, (N<u>H</u>)); 3.74(d, ³J_{HP} 11.5Hz, 3H, OMe)); 1.98-1.75(m, 2H, (CH₃<u>CH</u>₂)); 1.64(dd, ³J_{HH} 8.5Hz, ⁴J_{HH} 3.25Hz, 3H, (=C<u>CH</u>₃)); 0.85(t, 3H, (<u>CH</u>₃CH₂)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 16.9; cryst., m.p. (°C) uncorrected 145-147, Yield (%) 81.

Synthesis of compounds 3a-l

General Procedure:

To a solution of 5*mmol* of the appropriate methyl-N-alkyl(phenyl)-(3-methylalk-1,2-dienyl)phosphonamidates (**2a-f**) in methylene chloride a solution of 5*mmol* of the appropriate electrophile (PhSBr, PhSeBr) was added at low temperature (-12 to -10° C). The solvent was then removed *in vacuo* and the residue was purified by chromatography (50g silicagel, hexane/ethylacetate 1:1.

 $(5,5-Dimethyl-2-oxo-4-phenylsulfenyl-2,5-dihydro-2^{5}-[1,2]oxaphosphol-2-yl)-propylamine$ **3a** $. C₁₄H₂₀NO₂PS, Calcd.: P 10.42, N 4.71, S 10.78%, Found: P 10.40, N 4.68, S 10.72%; IR: v (cm⁻¹) 1592 (C=C), 1259 (P=O), 1000 (P=O), ¹H NMR (CDCl₃) <math>\delta$ /ppm: 7.56-7.46(m, 2H, (Ph)); 7.29-7.23(m, 3H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.54(m, 2H, (CH₃CH₂CH₂N)); 1.46(s, 3H, =C<u>CH₃</u>)); 1.51(s, 3H, (=C<u>CH₃</u>)); 2.00(d, ²J_{HP} 10.00Hz, 1H, (N<u>H</u>)); 1.28-1.19(m, 2H, (CH₃CH₂CH₂N)); 0.91(t, 3H, (<u>CH₃CH₂CH₂N)</u>); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 29.0; cryst., m.p. (°C) uncorrected 113-116, Yield (%) 85.

(5,5-Dimethyl-2-oxo-4-phenylsulfenyl-2,5-dihydro- $2\lambda^5$ -[1,2]oxaphosphol-2-yl)-butylamine **3b**. C₁₅H₂₂NO₂PS, Calcd.: P 9.95, N 4.50, S 10.30%, Found: P 9.91, N 4.48, S 10.28%; IR: v (cm⁻¹) 1590 _(C=C), 1260 _(P=O), 1000 _(P-O-C), ¹H NMR (CDCl₃): δ/ppm 7.64-7.60(m, 5H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.66-2.53(m, 2H, (CH₃CH₂CH₂CH₂N)); 2.00(d, ²J_{HP} 10.00Hz, 1H, (N<u>H</u>)); 1.46(s, 3H, =C<u>CH₃</u>)); 1.51(s, 3H, (=C<u>CH₃</u>)); 1.27-1.18(m, 2H, (CH₃CH₂CH₂CH₂N)); 1.16-0.99(m, 2H, (CH₃CH₂CH₂CH₂N)); 0.63(t, 3H, (<u>CH₃CH₂CH₂CH₂CH₂N)); ³¹P NMR(CDCl₃) δ/ppm: ³¹P 28.9; cryst., m.p. (°C) uncorrected 115-118, Yield (%) 84.</u>

 $(5,5-Dimethyl-2-oxo-4-phenylsulfenyl-2,5-dihydro-2 \lambda^{5}-[1,2]oxaphosphol-2-yl)-phenylylamine$ **3c** $. C₁₇H₁₈NO₂PS, Calcd.: P 9.35, N 4.22, S 9.68%, Found: P 9.33, N 4.19, S 9.65%; IR: v (cm⁻¹) 1589 (C=C), 1257 (P=O), 1000 (P-O-C), ¹H NMR (CDCl₃): <math>\delta$ /ppm 7.63-7.59(m, 2H, (Ph)); 7.49-7.37(m, 3H, (Ph)); 7.26-7.18(m, 2H, (Ph)); 7.07-6. 95(m, 3H, (Ph)); 5.44(dd, ²J_{HP} 28.05, ³J_{HH} 5.00Hz, 1H, (HC=)); 1.46(s, 3H, =C<u>CH</u>₃)); 1.51(s, 3H, (=C<u>CH</u>₃)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 30.0; cryst., m.p. (°C) uncorrected 123-126, Yield (%) 82.

(5-*Ethyl*-5-*methyl*-2-*oxo*-4-*phenylsulfenyl*-2,5-*dihydro*-2 λ^{5} -[1,2]*oxaphosphol*-2-*yl*)-*propylamine* **3d**. C₁₅H₂₂NO₂PS, Calcd.: P 9.95, N 4.50, S 10.30%, Found: P 9.91, N 4.48, S 10.28%; IR: v (cm⁻¹) 1592 _(C=C), 1259 _(P=O), 1000 _(P-O-C), ¹H NMR (CDCl₃): δ /ppm 7.56-7.46(m, 2H, (Ph)); 7.29-7.23(m, 3H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.67-2.54(m, 2H, (CH₃CH₂CH₂N)); 1.82-1.68(m, 3H, (<u>NH</u>), (CH₃CH₂)); 1.49(dd, ³J_{HH} 10,00Hz, ⁴J_{HH} 3.53Hz, 3H, (=C<u>CH</u>₃)); 1.28-1.19(m, 2H, (CH₃CH₂CH₂N)); 0.77(dt, ²J_{HH} 1.25Hz, 3H, (<u>CH</u>₃CH₂)); 0.91(t, 3H, (<u>CH</u>₃CH₂CH₂N)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 29.8; cryst., m.p. (^oC) uncorrected 114-116, Yield (%) 84.

 $(5-Ethyl-5-methyl-2-oxo-4-phenylsulfenyl-2,5-dihydro-2 \ \lambda^{5}-[1,2]oxaphosphol-2-yl)-butylamine \ \textbf{3e}. \\ C_{16}H_{24}NO_2PS, Calcd.: P 9.52, N 4.30, S 9.85\%, Found: P 9.50, N 4.28, S 9.81\%; IR: v (cm⁻¹) 1590 (C=C), 1260 (P=O), 1000 (P-O-C), ¹H NMR (CDCl_3): \delta/ppm 7.64-7.60(m, 5H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.66-2.53(m, 2H,(CH_3CH_2CH_2CH_2CH_2N)); 1.82-1.68(m, 3H, (NH), (CH_3CH_2)); 1.49(dd, ³J_{HH} 10,00Hz, ⁴J_{HH} 10,00Hz, ⁴J_{H$



ASN, Vol 4, No 1, Pages 6-12, 2017 3.53Hz, 3H, (=C<u>CH</u>₃)); 1.27-1.18(m, 2H, (CH₃CH₂CH₂CH₂N)); 1.16-0.99(m, 2H, (CH₃<u>CH</u>₂CH₂CH₂N)); 0.77(dt, ²J_{HH} 1.25Hz, 3H, (<u>CH</u>₃CH₂)); 0.63(t, 3H, (<u>CH</u>₃CH₂CH₂CH₂N)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 32.0; cryst., m.p. (°C) uncorrected 116-118, Yield (%) 82.

 $\begin{array}{l} (5-Ethyl-5-methyl-2-oxo-4-phenylsulfenyl-2,5-dihydro-2 \ \lambda^{5}-[1,2]oxaphosphol-2-yl)-phenylylamine \ \textbf{3f}. \\ C_{18}H_{20}NO_{2}PS, Calcd.: P 8.97, N 4.05, S 9.22\%, Found: P 8.94, N 4.00, S 9.22\%; IR: v (cm⁻¹) 1589 (C=C), 1257 (P=O), 1000 (P-O-C), ¹H NMR (CDCl_{3}): \\ \delta/ppm 7.63-7.59(m, 2H, (Ph)); 7.49-7.37(m, 3H, (Ph)); 7.26-7.18(m, 2H, (Ph)); 7.07-6.95(m, 3H, (Ph)); 5.44(dd, ^{2}J_{HP} 28.05, ^{3}J_{HH} 5.00Hz, 1H, (HC=)); 1.98-1.75(m, 2H, (CH_{3}CH_{2})); 1.64(dd, ^{3}J_{HH} 8.5Hz, ^{4}J_{HH} 3.25Hz, 3H, (=CCH_{3})); 0.85(t, 3H, (CH_{3}CH_{2})); ^{31}P NMR(CDCl_{3}) \ \delta/ppm: ^{31}P 27.9; cryst., m.p. (^{\circ}C) uncorrected 125-127, Yield (\%) 80. \end{array}$

 $(5,5-Dimethyl-2-oxo-4-phenylselenenyl-2,5-dihydro-2 \lambda^{5}-[1,2] oxaphosphol-2-yl)-propylamine$ **3g** $. \\ C_{14}H_{20}NO_{2}PSe, Calcd.: P 9.92, N 4.48%, Found: P 9.90, N 4.43%; IR: v (cm⁻¹) 1592 (C=C), 1259 (P=O), 1000 (P=O-C), ^1H NMR (CDCl_3): \delta/ppm 7.56-7.46(m, 2H, (Ph)); 7.29-7.23(m, 3H, (Ph)); 5.35(dd, ^2J_{HP} 27.75Hz, ^3J_{HH} 3.75Hz, 1H, (HC=)); 2.54(m, 2H, (CH_{3}CH_{2}CH_{2}N)); 1.46(s, 3H, =CCH_{3})); 1.51(s, 3H, (=CCH_{3})); 2.00(d, ^2J_{HP} 10.00Hz, 1H, (NH)); 1.28-1.19(m, 2H, (CH_{3}CH_{2}CH_{2}N)); 0.91(t, 3H, (CH_{3}CH_{2}CH_{2}N)); ^{31}P NMR(CDCl_{3}) \delta/ppm: ^{31}P 29.7; cryst., m.p. (°C) uncorrected 114-116, Yield (%) 84.$

 $(5,5-Dimethyl-2-oxo-4-phenylselenenyl-2,5-dihydro-2 \lambda^{5}-[1,2]oxaphosphol-2-yl)-butylamine$ **3h** $. C₁₅H₂₂NO₂PSe, Calcd.: P 9.49, N 4.29%, Found: P 9.45, N 4.23%; IR: v (cm⁻¹) 1590 _(C=C), 1260 _(P=O), 1000 _(P-O-C), ¹H NMR (CDCl₃): <math>\delta$ /ppm 7.64-7.60(m, 5H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.66-2.53(m, 2H, (CH₃CH₂CH₂CH₂N)); 2.00(d, ²J_{HP} 10.00Hz, 1H, (N<u>H</u>)); 1.46(s, 3H, =C<u>CH₃</u>)); 1.51(s, 3H, (=C<u>CH₃</u>)); 1.27-1.18(m, 2H, (CH₃CH₂CH₂CH₂CH₂N)); 1.16-0.99(m, 2H, (CH₃CH₂CH₂CH₂N)); 0.63(t, 3H, (<u>CH₃CH₂CH₂CH₂CH₂N)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 30.5; cryst., m.p. (°C) uncorrected 119-120, Yield (%) 86.</u>

 $\begin{array}{l} (5,5-Dimethyl-2-oxo-4-phenylselenenyl-2,5-dihydro-2 \ \lambda^5-[1,2]oxaphosphol-2-yl)-phenylylamine \ \textbf{3i}.\\ C_{17}H_{18}NO_2PSe, Calcd.: P 8.94, N 4.04\%, Found: P 8.90, N 4.00\%; IR: v (cm⁻¹) 1589 (C=C), 1257 (P=O), 1000 (P-O-C), \ ^1H NMR (CDCl_3): \delta/ppm 7.63-7.59(m, 2H, (Ph)); 7.49-7.37(m, 3H, (Ph)); 7.26-7.18(m, 2H, (Ph)); 7.07-6. 95(m, 3H, (Ph)); 5.44(dd, ^2J_{HP} 28.05, ^3J_{HH} 5.00Hz, 1H, (HC=)); 1.46(s, 3H, =C\underline{CH}_3)); 1.51(s, 3H, (=C\underline{CH}_3)); \ ^{31}P NMR(CDCl_3) \ \delta/ppm: \ ^{31}P 28.8; cryst., m.p. (^{\circ}C) uncorrected 124-126, Yield (\%) 82. \end{array}$

 $(5-Ethyl-5-methyl-2-oxo-4-phenylselenenyl-2,5-dihydro-2 \lambda^{5}-[1,2]oxaphosphol-2-yl)-propylamine$ **3j** $. \\ C_{15}H_{22}NO_{2}PSe, Calcd.: P 9.49, N 4.29%, Found: P 9.45, N 4.23%; IR: v (cm⁻¹) 1592 (C=C), 1259 (P=O), 1000 (P=O-C), ^1H NMR (CDCl_3): <math>\delta$ /ppm 7.56-7.46(m, 2H, (Ph)); 7.29-7.23(m, 3H, (Ph)); 5.35(dd, ^2J_{HP} 27.75Hz, ^3J_{HH} 3.75Hz, 1H, (HC=)); 2.67-2.54(m, 2H, (CH_{3}CH_{2}CH_{2}N)); 1.82-1.68(m, 3H, (<u>NH</u>), (CH_{3}CH_{2})); 1.49(dd, ^3J_{HH} 10,00Hz, ^4J_{HH} 3.53Hz, 3H, (=C<u>CH_3</u>)); 1.28-1.19(m, 2H, (CH_{3}CH_{2}CH_{2}N)); 0.77(dt, ^2J_{HH} 1.25Hz, 3H, (<u>CH_{3}CH_{2})); 0.91(t, 3H, (CH_{3}CH_{2}CH_{2}N)); ^{31}P NMR(CDCl_{3}) \delta/ppm: ³¹P 29.8; cryst., m.p. (°C) uncorrected 115-117, Yield (%) 83.</u>

 $(5-Ethyl-5-methyl-2-oxo-4-phenylselenenyl-2,5-dihydro-2 \lambda^{5}-[1,2]oxaphosphol-2-yl)-butylamine$ **3k** $. C₁₆H₂₄NO₂PSe, Calcd.: P 9.10, N 4.11%, Found: P 9.06, N 4.08%; IR: v (cm⁻¹) 1590 _(C=C), 1260 _(P=O), 1000 _(P-O-C), ¹H NMR (CDCl₃): <math>\delta$ /ppm 7.64-7.60(m, 5H, (Ph)); 5.35(dd, ²J_{HP} 27.75Hz, ³J_{HH} 3.75Hz, 1H, (HC=)); 2.66-2.53(m, 2H,(CH₃CH₂CH₂CH₂N)); 1.82-1.68(m, 3H, (<u>NH</u>), (CH₃CH₂)); 1.49(dd, ³J_{HH} 10,00Hz, ⁴J_{HH} 3.53Hz, 3H, (=C<u>CH</u>₃)); 1.27-1.18(m, 2H, (CH₃CH₂CH₂CH₂CH₂N)); 1.16-0.99(m, 2H, (CH₃CH₂CH₂CH₂N)); 0.77(dt, ²J_{HH} 1.25Hz, 3H, (<u>CH</u>₃CH₂)); 0.63(t, 3H, (<u>CH</u>₃CH₂CH₂CH₂N)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 30.9; cryst., m.p. (°C) uncorrected 120-122, Yield (%) 82.



ASN, Vol 4, No 1, Pages 6-12, 2017

(5-*Ethyl*-5-*methyl*-2-*oxo*-4-*phenylselenenyl*-2,5-*dihydro*-2 λ^{5} -[1,2]*oxaphosphol*-2-*yl*)-*phenylylamine* **3l**. C₁₈H₂₀NO₂PSe, Calcd.: P 8.59, N 3.88%, Found: P 8.55, N 3.85%; IR: ν (cm⁻¹) 1589 (C=C), 1257 (P=O), 1000 (P-O-C), ¹H NMR (CDCl₃): δ/ppm 7.63-7.59(m, 2H, (Ph)); 7.49-7.37(m, 3H, (Ph)); 7.26-7.18(m, 2H, (Ph)); 7.07-6.95(m, 3H, (Ph)); 5.44(dd, ²J_{HP} 28.05, ³J_{HH} 5.00Hz, 1H, (HC=)); 1.98-1.75(m, 2H, (CH₃CH₂)); 1.64(dd, ³J_{HH} 8.5Hz, ⁴J_{HH} 3.25Hz, 3H, (=C<u>CH₃</u>)); 0.85(t, 3H, (<u>CH₃CH₂</u>)); ³¹P NMR(CDCl₃) δ/ppm: ³¹P 31.7; cryst., m.p. (°C) uncorrected 127-129, Yield (%) 81.

Synthesis of compounds 4a-f General Procedure:

To a solution of *5mmol* of the appropriate methyl-N-alkyl(phenyl)-(3-methylalk-1,2-dienyl)phosphonamidates (**2a-f**) in methylene chloride a solution of *5mmol* of dialkylamine was added at -8°C. After warm up to room temperature and additional stirring for an hour, 10% aqueous HCl was added. The organic phase was separated and the residue was extracted with CHCl₃. The organic phases were dried with MgSO₄, the solvent was then removed *in vacuum* and the residue was distilled.

 $\begin{array}{l} \textit{Methyl-P-(3-methyl-2-oxopentyl)-N-propylphosphonamidate $ \textbf{4b}. C_9H_{21}NO_3P; Calcd.: P 13.93, N 6.30 \%; Found: P 13.81, N 6.25 \%; IR: v (cm⁻¹) 1260 (P=O), 1690 (C=O), ¹H NMR (CDCl_3): <math>\delta$ /ppm 3.78(d, ²J_{HP} 10.9Hz, 3H, (OMe)); 3.69 (m, 1H (NH)); 2.84(d, ²J_{HP} 11.9Hz, 2H (CH_2)); 2.63(t, ²J_{HH} 7.1Hz, 2H, (CH_3CH_2CH_2N)); 2.36(q, ²J_{HH} 7.0Hz, ³J_{HH} 6.8Hz 1H (CH)); 1.06(q, ²J_{HH} 7.0Hz, ²J_{HH} 8.0Hz, 2H(CH_3CH_2CH_2N)); 1.68 (q, ²J_{HH} 7.0Hz, ²J_{HH} 8.0Hz, 2H (CH_3CH_2)); 1.04 (d, ²J_{HH} 6.8Hz, 3H (CH_3)); 0.94 (t, ²J_{HH} 8.0Hz, 3H (CH_3CH_2)); 0.84 (t, ²J_{HH} 8.0Hz, 3H (CH_3CH_2CH_2N)); ³¹P NMR(CDCl_3) δ /ppm: ³¹P 16.8; oil; Yield (%) 82.

 $\begin{array}{l} \textit{Methyl -P-(3-methyl-2-oxobutyl)-N-butyl phosphonamidate } \textbf{4c}. C_{10}H_{21}NO_3P; Calcd.: P 13.22, N 5.98 \%; Found: P 13.19, N 5.82 \%; IR: v (cm⁻¹) 1238 (P=O), 1700 (C=O), ¹H NMR (CDCl_3): \delta/ppm 3.78(d, ³J_{HP} 10.09Hz, 3H, (O\underline{Me})); 2.56(t, ²J_{HH} 6.8Hz, 1H, (C\underline{H})); 2.63(t, ²J_{HH} 7.1Hz, 2H, (CH_3CH_2CH_2CH_2N)); 2.50(d, ²J_{HP} 11.9Hz, 2H (C\underline{H}_2)); 1.04(d, ²J_{HH} 6.8Hz, 6H, CH(\underline{CH}_3)_2); 3.69(m, 1H, (NH); 1.52(q, ²J_{HH} 7.0Hz, ²J_{HH} 6.8 Hz, 2H(CH_3CH_2C\underline{H}_2CH_2N)); 1.30 (q, ²J_{HH} 7.1Hz, ²J_{HH} 8.0Hz, 2H (CH_3C\underline{H}_2CH_2C\underline{H}_2N)); 0.89 (t, ²J_{HH} 8.0Hz, 3H (C\underline{H}_3CH_2C\underline{H}_2CH_2CH_2N)); 3^{31}P NMR(CDCl_3) \delta/ppm: ³¹P 17.1; oil; Yield (\%) 85. \end{array}$

Methyl- P-(3-methyl-2-oxopentyl) -N-butylphosphonamidate **4d**. $C_{11}H_{23}NO_3P$; Calcd.: P 12.47, N 5.63%; Found: P 12.35, N 5.44; IR: v (cm⁻¹) 1259 (P=O), 1700 (C=O), ¹H NMR (CDCl₃): δ /ppm 3.78(d, ²J_{HP} 10.9Hz, 3H, (O<u>Me</u>)); 3.69 (m, 1H (N<u>H</u>)); 2.84(d, ²J_{HP} 11.9Hz,2H (C<u>H</u>₂)); 2.63(t, ²J_{HH} 7.1Hz, 2H, (CH₃CH₂CH₂C<u>H</u>₂N)); 2.36(q, ²J_{HH} 7.0Hz, ³J_{HH} 6.8Hz 1H (CH)); 1.52(q, ²J_{HH} 7.0Hz, ²J_{HH} 6.8 Hz, 2H(CH₃CH₂CH₂CH₂N)); 1.68 (q, ²J_{HH} 7.0Hz, ²J_{HH} 8.0Hz, 2H (CH₃C<u>H</u>₂CH₂C<u>H</u>₂N)); 1.04 (d, ²J_{HH} 7.0Hz, ³J_{HH} 8.0Hz, 3H (C<u>H</u>₃)); 0.94 (t, ²J_{HH} 8.0Hz, 3H (C<u>H</u>₃CH₂)); 0.89 (t, ²J_{HH} 8.0Hz, 3H (C<u>H</u>₃CH₂CH₂CH₂N)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 16.8; oil ; Yield (%) 82.

Methyl- P-(3-methyl-2-oxobutyl)-N-phenylphosphonamidate **4e**. $C_{12}H_{17}NO_3P$; Calcd.: P 12.18, N 5.50 %; Found: P 12.09, N 5.43 %; IR: v (cm⁻¹) 1259 (P=O), 1700 (C=O), ¹H NMR (CDCl₃): δ /ppm 3.38(d, ²J_{HP} 11.25Hz, 3H, (OMe)); 7.29-7.17(m, 2H, (Ph)); 7.05(d, ²J_{HH} 7.75Hz, 1H, (Ph)); 6.89(t, ²J_{HH} 7.25Hz, 2H, (Ph)); 6.70(m, 1H, (<u>NH</u>); 1.49(dd, ³J_{HH} 10,00Hz, ⁴J_{HH} 3.53Hz, 6H, (CH<u>CH</u>₃)); 2.56(t, ²J_{HH} 6.8Hz, 1H, (C<u>H</u>)); 2.84(d, ²J_{HP} 11.9Hz, 2H (C<u>H</u>₂)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 17.3; oil; Yield (%) 81.



Methyl- P-(3-methyl-2-oxopentyl)-N-phenylphosphonamidate **4f.** $C_{13}H_{19}NO_2P$; Calcd.: P 11.54, N 5.22 %; Found: P 11.29, N 5.12 %; IR: v (cm⁻¹) 1259 (P=O), 1700 (C=O), ¹H NMR (CDCl₃): δ /ppm 7.29-7.17(m, 2H, (Ph)); 7.05(d, ²J_{HH} 7.75Hz, 1H, (Ph)); 6.89(t, ²J_{HH} 7.25Hz, 2H, (Ph)); 6.70(m, 1H, (<u>NH</u>); 3.74(d, ³J_{HP} 11.5Hz, 3H, OMe)); 1.68 (q, ²J_{HH} 7.0Hz, ²J_{HH} 8.0Hz, 2H (CH₃C<u>H</u>₂)); 1.04 (d, ²J_{HH} 6.8Hz, 3H (C<u>H</u>₃)); 0.94 (t, ²J_{HH} 8.0Hz, 3H (C<u>H</u>₃CH₂)); 2.56(t, ²J_{HH} 6.8Hz, 1H, (C<u>H</u>)); 2.84(d, ²J_{HP} 11.9Hz, 2H (C<u>H</u>₂)); ³¹P NMR(CDCl₃) δ /ppm: ³¹P 16.9; oil; Yield (%) 84.

Acknowledgement

The authors are indebted to Prof. S. Simova and to all the staff of the National Centre of NMR Spectroscopy, Bulgarian Academy of Sciences.

References

- [1]. Alabugin, I. V., V. K. Brel, Usp. Khim.; 2005, 66, 156
- [2]. Angelov, Ch. M., D. D. Enchev, Phosphorus Sulfur Silicon and the Related Elem.; 1987, 34, 163
- [3]. Enchev, D. D., Phosphorus Sulfur Silicon and the Related Elem.; 2005, 180, 2131
- [4]. Enchev, D. D., Phosphorus Sulfur Silicon and the Related Elem.; 2005, 180, 2137
- [5]. Enchev, D. D., Phosphorus Sulfur Silicon and the Related Elem.; 2005, 180, 2141
- [6]. Enchev, D. D., Phosphorus Sulfur Silicon and the Related Elem.; 2005, 180, 2211
- [7]. Enchev, D. D., *Heteroatom Chem.*; 2005, 16, 156
- [8]. Enchev, D. D., S. P. Stankolov, Phosphorus Sulfur Silicon and the Related Elem.; 2007, 182, 1857
- [9]. Simonin, M. P., M. J. Pauet, , J. M. Gence, C. Paumier, Org. Magn. Reson., 1976, 8, 508
- [10]. Angelov, Ch. M., M. Kirilov, B.I. Ionin , A. A Petrov, Rus. J. Gen. Chem., 1979, 49, 2225